



FOR IMMEDIATE RELEASE

Allison Potter
Pascale Communications, LLC
Phone: +1 412.228.1678
Email: allison@pascalecommunications.com

Mike Ford
Santen Inc.
Phone: +1 415.268.9058
Email: mford@santeninc.com

SANTEN INC. BUILDS GLOBAL MEDICAL AFFAIRS TEAM

EMERYVILLE, CA- July 12, 2011- Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd. of Osaka, Japan, announced the addition of four new employees to the Global Clinical and Medical Affairs Group. “This new team brings a wealth of experience and knowledge with drug development, clinical trials and safety. We are confident that their combined expertise will aid Santen Inc. in bringing new and innovative products to the global market,” states Naveed Shams, VP of Clinical Affairs.

Joel Naor, MD, MSc, MBA will head the newly established Medical Affairs function in Research and Development’s Global Clinical Development & Medical Affairs Group. In this new role at Santen he will be responsible for developing and implementing a global medical affairs strategy and will assist in developing and managing Santen’s pipeline.

As an ophthalmologist, Dr. Naor brings to Santen over a decade of drug development experience as well as familiarity with patient care. Dr. Naor played a significant role in the joint QLT / Novartis development of Visudyne® and was a key contributor to the development of Ozurdex® by Allergan, serving as the global project team leader and a member of the global medical affairs group. As the Chief Medical Officer of Macusight, Dr. Naor led the clinical development of Sirolimus for the treatment of ocular conditions. Most recently, he served as VP of drug development at Ora Inc. where he supported its drug and business development activities on the West Coast. Dr. Naor earned his M.D. from the Technion - Israel Institute of Technology and underwent cornea and external disease training at the University of Toronto where he also obtained his M.Sc. in epidemiology. He also holds a MBA from Simon Fraser University in Vancouver.

Laura Wilson, MD has joined Santen as Senior Medical Director, & Head of Retina Clinical Sciences in the Global Clinical Development and Medical Affairs group. In her new role she will take over responsibility for Clinical Science activities in the Retina space within the newly created Clinical Science Group within GCD & MA. Additionally, Dr. Wilson will be the Medical Monitor for the Phase III clinical trial in non-infectious uveitis affecting the posterior segment of the eye. Prior to joining Santen, Dr. Wilson was a Medical Director at Genentech/Roche where she made significant contributions to the development and commercialization of Lucentis. Dr. Wilson is a board certified Internist with over 15 years of clinical experience. Prior to joining industry, she was a Hospitalist at Kaiser Permanente..

Dr. Wilson attended Finch University of Health Sciences/The Chicago Medical School in Chicago, IL and completed her residency in Internal Medicine at Kaiser Permanente in San Francisco, CA.

Marye Ellen Valentine, MS has joined the Global Clinical and Medical Affairs Group as Director of Clinical Operation – Posterior Segment. Ms. Valentine comes to us with many years of Global Clinical Development experience at Alexion Pharmaceuticals, Bristol-Myers Squibb, Cerus Corporation, Guidant Corporation, Cardiac Pathways and Baxter Healthcare.

Lisa Lawrence-Miyasaki, RN, BSN, MA joined the Global Clinical and Medical Affairs Group as Director of Drug Safety. Ms. Lawrence-Miyasaki comes to Santen with more than 15 years of global drug safety experience at IPSEN and Genentech, including Drug Safety Lead on the Lucentis Project at Genentech. She also worked closely with Novartis Pharmaceuticals on the global drug safety database.

About Santen Inc.

Santen Inc., based in Emeryville, California, is the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a billion-dollar global company headquartered in Osaka, Japan since 1890. Recently, the company announced its relocation of the U.S. corporate headquarters from Napa to Emeryville, California in preparation for substantial expansion of the organization.

Santen researches, develops and markets ophthalmic products for physicians worldwide. Santen has subsidiaries in the U.S., Europe and Asia, including its wholly-owned California-based Santen Inc. Santen Inc. also maintains a satellite business development office in Irvine, California which provides direct access to the regional cluster of ophthalmic companies operating in that area. Among prescription ophthalmic pharmaceuticals, Santen holds the top share within the Japanese and Chinese markets and is one of the leading ophthalmic companies worldwide. Santen's global product pipeline includes a number of prescription pharmaceuticals in varying clinical trial phases. A detailed listing, as well as additional corporate information, is available online at www.santeninc.com.

###